Thus, targeting CDCA8 could be a next-line molecular therapy to effectively reduce the tumor burden and block metastasis or recurrence by eliminating both cancer cells and cancer stem cells in the HCC microenvironment. The gene discussed is CDCA8; the disease is neoplasm.